After 4 years of follow-up, the mortality rate was 4.8%, 1 patient had relapsed and 6 patients (29%) had restarted TNF-α antagonist treatment after appropriate antituberculous therapy, without reactivation.
Our data support the concept that TNFα antagonists can be restarted in patients diagnosed with TB provided adequate antituberculous treatment has been completed.
Tumor Necrosis Factor α (TNF-α) induces intracellular death of Mycobacterium tuberculosis, macrophage apoptosis and granuloma formation [1] [2] [3] . Keane et al. [4] were the first to describe an increased incidence of TB in patients with rheumatoid arthritis (RA) treated with TNF-α blockers. The relative risk of developing TB whilst on this therapy in this patient group has been estimated in the USA and Europe at ≥4 [4] [5] [6] [7] . In France, a national Overall, 25 definite or probable TB cases were reported. 21 cases from 19 different centers were retained for analysis (2 cases could not be validated by an on-site visit, the same patient was declared twice in one case and the diagnosis of TB was not retracted in the last case).
The underlying inflammatory disease, patients' demographic characteristics and concomitant immunosuppressive treatments are shown in Table 1 Our data strongly suggest that TB is not a contraindication to restarting anti-TNF-α therapy if the underlying inflammatory disease requires it. 
